Revascularization of low-surgical risk patients with disease of the left main coronary artery: a fresh look at the evidence.
Baigent C. and Sádaba R., (2023), Eur Heart J
Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP).
Herrington WG. et al, (2023), Kidney Int Rep, 8, 1489 - 1495
Revascularization of low-surgical risk patients with disease of the left main coronary artery: a fresh look at the evidence.
Baigent C. and Sádaba R., (2023), Eur J Cardiothorac Surg, 64
A meta-analysis of GFR slope as a surrogate endpoint for kidney failure.
Inker LA. et al, (2023), Nat Med, 29, 1867 - 1876
Empagliflozin in Patients with Chronic Kidney Disease. Reply.
Herrington WG. et al, (2023), N Engl J Med, 388, 2301 - 2302
Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors.
Chapman D. et al, (2023), Kidney Int, 103, 787 - 790
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK.
Zhou J. et al, (2023), Pharmacoeconomics
Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD.
Collier W. et al, (2023), Clin J Am Soc Nephrol, 18, 183 - 192
Empagliflozin in Patients with Chronic Kidney Disease.
The EMPA-KIDNEY Collaborative Group None. et al, (2023), N Engl J Med, 388, 117 - 127
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert M. et al, (2023), European Respiratory Journal, 61
Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: A Mendelian Randomization Study.
Donovan K. et al, (2023), Clin J Am Soc Nephrol, 18, 17 - 27
Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology.
Staplin N. et al, (2022), Hypertension, 79, 2671 - 2681
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Nuffield Department of Population Health Renal Studies Group None. and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium None., (2022), Lancet, 400, 1788 - 1801
Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses.
Gaziano L. et al, (2022), Circulation
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.
Cholesterol Treatment Trialists' Collaboration None., (2022), Lancet, 400, 832 - 845
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.
Nazarzadeh M. et al, (2022), Lancet Diabetes Endocrinol, 10, 645 - 654
Systematic approach to outcome assessment from coded electronic healthcare records in the DaRe2THINK NHS-embedded randomized trial.
Wang X. et al, (2022), Eur Heart J Digit Health, 3, 426 - 436
CODE-EHR best-practice framework for the use of structured electronic health-care records in clinical research.
Kotecha D. et al, (2022), Lancet Digit Health
Individual participant data meta-analysis of muscle symptoms in large-scale randomised double-blind trials of statin therapy
BAIGENT C. et al, (2022), The Lancet